Using nanotechnology, University of California, Los Angeles researchers discover cancer cells 'feel' much softer than normal cells

Los Angeles 02 December 2007A multi-disciplinary team of University of California, Los Angeles (UCLA) scientists were able to differentiate metastatic cancer cells from normal cells in patient samples using leading-edge nanotechnology that measures the softness of the cells. The study, published December 2, 2007 in the advance on-line edition of the journal Nature Nanotechnology, represents one of the first times researchers have been able to take living cells from cancer patients and apply nanotechnology to analyse them and determine which were cancerous and which were not. The nano science measurements may provide a potential new method for detecting cancer, especially in cells from body cavity fluids where diagnosis using current methods is typically very challenging. The method also may aid in personalizing treatments for patients.

Advertisement

When cancer is becoming metastatic, or invading other organs, the diseased cells must travel throughout the body. Because the cells need to enter the bloodstream and maneuver through tight anatomical spaces, cancer cells are much more flexible, or softer, than normal cells. These spreading, invading cancer cells can cause a build-up of fluids in body cavities such as the chest and abdomen. But fluid build-up in patients does not always mean cancer cells are present. If the fluid could be quickly and accurately tested for the presence of cancer, oncologists could make better decisions about how aggressive a treatment should be administered or if any treatment is necessary at all.

In this study, researchers collected fluid from the chest cavities of patients with lung, breast and pancreatic cancers, a relatively non-invasive procedure. One problem with diagnosing metastatic disease in this setting is that cancer cells and normal cells in body cavity fluids look very similar under an optical microscope, according to Jianyu Rao, a researcher at UCLA's Jonsson Cancer Center, an associate professor of pathology and laboratory medicine and one of the study's senior authors. Conventional diagnostic methods detect about 70 percent of cases where cancer cells are present in the fluid, missing about 30 percent of cases.

"We detect cancer cells typically by looking at them under a microscope after the cells are fixed and stained with chemicals, which is really an antiquated method", Jianyu Rao stated. "Usually the cancer cells have larger nuclei and other subtle features. However, the normal cells from body cavity fluids can look almost identical to cancer cells under an optical microscope. While staining for tumour protein markers could increase diagnostic accuracy, what we were missing was a way to determine if cancer cells have different mechanical properties than normal cells."

Employing one of the most valuable tools in the nanotechnology arsenal, the research team used an Atomic Force Microscope (AFM) to measure cell softness. Since the cells being analysed were less than half the diameter of a human hair, researchers needed a very precise and delicate instrument to measure resistance in the cell membrane, according to James Gimzewski, professor of chemistry and biochemistry, a member of the California NanoSystems Institute and also one of the study's senior authors.

"We had to measure the softness of the cell without bursting it", James Gimzewski stated. "Otherwise, it's like trying to measure the softness of a tomato using a hammer." The AFM uses a minute, sharp tip on a spring to push against the cell surface and determine the degree of softness. Think of it as an extension of a doctor's hands performing a physical examination to determine disease, James Gimzewski explained.

"You look at two tomatoes in the supermarket and both are red. One is rotten, but it looks normal", James Gimzewski stated. "If you pick up the tomatoes and feel them, it's easy to figure out which one is rotten. We're doing the same thing. We're poking and quantitatively measuring the softness of the cells."

After probing a cell, the AFM assigns a value that represents how soft a cell is based on the resistance encountered. What the team found was that the cancer cells were much softer than the normal cells and they were similarly soft with very little variation in gradation. The normal, healthy cells from the same specimen were much stiffer than the cancer cells and, in fact, the softness values assigned to each group did not overlap at all, making diagnosis using this nanomechanical measurement easier and more accurate.

"It was fascinating to find such striking characteristics between the metastatic cancer cells and normal cells", stated Sarah Cross, a graduate student in the chemistry and biochemistry department and a study author. "The metastatic cancer cells were extremely soft and easily distinguishable from the normal cells despite similarities in appearance. And we're looking at live cells taken from human patients, so that makes this is a unique finding."

Calvin Quate of Stanford University, the co-inventor of the Atomic Force Microscope, stated that the UCLA study breaks new ground. "This manuscript is the first that directly shows a relationship between the nanomechanical properties and physiological function in clinical samples from patients with suspected cancer", noted Calvin Quate, 1992 Medal of Science recipient.

National breast cancer expert Susan Love said the study findings "open a new era for function-based tumor cell diagnostics." "With these findings, it is foreseeable that a combined biochemical, biophysical and morphological analysis for analysing human cytological specimens using AFM may be finally realized", stated Susan Love, president and medical director of the Susan Love Research Foundation and a clinical professor of surgery at UCLA.

Researchers next will explore whether the nanomechanical analysis can be used to personalize cancer treatment based on the characteristics of a patient's cancer cells. There are standard chemotherapy drugs that are used to treat metastatic cancer, according to Jianyu Rao, but response varies from patient to patient. If researchers could test the cancer cells beforehand, they could potentially apply therapies that would make the cells stiffer, making it more difficult for the diseased cells to spread through the body.

The study was a collaboration between the California NanoSystems Institute, the Jonsson Cancer Center and the Departments of Chemistry and Biochemistry and Pathology and Laboratory Medicine. In addition to Jianyu Rao, James Gimzewski and Sarah Cross, the research team included Yu-Sheng Jin.

UCLA's Jonsson Comprehensive Cancer Center comprises about 235 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the United States' largest comprehensive cancer centres, the Jonsson Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2007, the Jonsson Cancer Center was named the best cancer centre in California by U.S. News & World Report, a ranking it has held for eight consecutive years.

The California NanoSystems Institute (CNSI) is a multi-disciplinary research centre at UCLA whose mission is to encourage university-industry collaboration and to enable the rapid commercialization of discoveries in nanosystems. CNSI members include some of the world's pre-eminent scientists, and the work conducted at the institute represents world-class expertise in five targeted areas of nanosystems-related research: renewable energy, environmental nanotechnology and nanotoxicology, nanobiotechnology and biomaterials, nanomechanical and nanofluidic systems, and nano-electronics, photonics and architectonics.


Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]